Nicox S.A. (NICXF)
USD 0.24
(0.0%)
USD 0.24
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -16.23 Million EUR | 30.57% |
| 2022 | -23.38 Million USD | -19.44% |
| 2021 | -15.96 Million USD | -166.44% |
| 2020 | -7.34 Million USD | 64.09% |
| 2019 | -20.46 Million USD | -4.57% |
| 2018 | -21.09 Million EUR | -3.37% |
| 2017 | -18.93 Million EUR | -192.7% |
| 2016 | -6.47 Million EUR | 66.5% |
| 2015 | -19.29 Million EUR | 2.63% |
| 2014 | -19.59 Million EUR | -31.7% |
| 2013 | -10.81 Million EUR | -48.77% |
| 2012 | -9.65 Million EUR | 32.51% |
| 2011 | -15 Million EUR | 64.41% |
| 2010 | -42.14 Million EUR | 21.1% |
| 2009 | -53.42 Million EUR | 31.8% |
| 2008 | -78.32 Million EUR | -113.61% |
| 2007 | -36.66 Million EUR | -40.68% |
| 2006 | -26.06 Million EUR | -57.85% |
| 2005 | -14.77 Million EUR | -17.85% |
| 2004 | -14.01 Million EUR | 26.41% |
| 2003 | -19.04 Million EUR | -3.82% |
| 2002 | -18.34 Million EUR | -18.03% |
| 2001 | -15.53 Million EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 FY | - EUR | 30.57% |
| 2023 Q2 | -8.36 Million USD | -84.8% |
| 2023 Q1 | -4.52 Million EUR | 62.27% |
| 2022 Q1 | -5.92 Million EUR | -7.67% |
| 2022 Q2 | -9.86 Million USD | -66.45% |
| 2022 Q3 | -5.23 Million EUR | 46.93% |
| 2022 Q4 | -11.99 Million USD | -129.23% |
| 2022 FY | - USD | -19.44% |
| 2021 Q2 | -11.71 Million EUR | -75.91% |
| 2021 Q3 | -2.93 Million EUR | 74.94% |
| 2021 Q4 | -5.5 Million EUR | -87.32% |
| 2021 FY | - USD | -166.44% |
| 2021 Q1 | -6.66 Million EUR | -575.5% |
| 2020 FY | - USD | 64.09% |
| 2020 Q4 | 1.4 Million EUR | 39.33% |
| 2020 Q3 | 1 Million EUR | 113.57% |
| 2020 Q1 | -3.78 Million EUR | 69.98% |
| 2020 Q2 | -7.4 Million EUR | -95.61% |
| 2019 FY | - USD | -4.57% |
| 2019 Q4 | -12.61 Million EUR | -89.66% |
| 2019 Q3 | -6.65 Million EUR | -122.94% |
| 2019 Q1 | -2.94 Million EUR | 57.45% |
| 2019 Q2 | -2.98 Million EUR | -1.38% |
| 2018 Q3 | -7 Million EUR | -33.08% |
| 2018 Q2 | -5.26 Million EUR | 5.21% |
| 2018 FY | - EUR | -3.37% |
| 2018 Q4 | -6.91 Million EUR | 1.32% |
| 2018 Q1 | -5.55 Million EUR | 0.0% |
| 2017 Q1 | -5.21 Million EUR | -14.12% |
| 2017 Q2 | -5.58 Million EUR | -7.06% |
| 2017 FY | - EUR | -192.7% |
| 2016 Q4 | -4.57 Million EUR | 2.78% |
| 2016 Q2 | -5.91 Million EUR | 2.49% |
| 2016 Q1 | -6.06 Million EUR | -44.26% |
| 2016 Q3 | -4.7 Million EUR | 20.53% |
| 2016 FY | - EUR | 66.5% |
| 2015 Q4 | -4.2 Million EUR | 2.68% |
| 2015 FY | - EUR | 2.63% |
| 2015 Q3 | -4.32 Million EUR | 3.34% |
| 2015 Q2 | -4.47 Million EUR | -3.69% |
| 2015 Q1 | -4.31 Million EUR | 0.0% |
| 2014 FY | - EUR | -31.7% |
| 2014 Q2 | -6.69 Million EUR | 0.64% |
| 2014 Q1 | -6.73 Million EUR | -39.53% |
| 2013 Q4 | -4.82 Million EUR | -14.27% |
| 2013 FY | - EUR | -48.77% |
| 2013 Q3 | -4.22 Million EUR | 12.83% |
| 2013 Q2 | -4.84 Million EUR | -13.35% |
| 2013 Q1 | -4.27 Million EUR | 6.6% |
| 2012 FY | - EUR | 32.51% |
| 2012 Q3 | -3.75 Million EUR | 15.4% |
| 2012 Q4 | -4.57 Million EUR | -21.79% |
| 2012 Q1 | 4.21 Million EUR | 166.71% |
| 2012 Q2 | -4.44 Million EUR | -205.36% |
| 2011 FY | - EUR | 64.41% |
| 2011 Q3 | -2.57 Million EUR | 30.27% |
| 2011 Q1 | -3.99 Million EUR | 34.44% |
| 2011 Q2 | -3.68 Million EUR | 7.73% |
| 2011 Q4 | -6.32 Million EUR | -145.86% |
| 2010 Q3 | -10.25 Million EUR | 49.37% |
| 2010 Q1 | -6.91 Million EUR | 0.0% |
| 2010 FY | - EUR | 21.1% |
| 2010 Q4 | -6.09 Million EUR | 40.56% |
| 2010 Q2 | -20.25 Million EUR | -192.73% |
| 2009 Q1 | -11.15 Million EUR | 0.0% |
| 2009 FY | - EUR | 31.8% |
| 2008 FY | - EUR | -113.61% |
| 2007 FY | - EUR | -40.68% |
| 2006 FY | - EUR | -57.85% |
| 2005 FY | - EUR | -17.85% |
| 2004 FY | - EUR | 26.41% |
| 2003 FY | - EUR | -3.82% |
| 2002 FY | - EUR | -18.03% |
| 2001 FY | - EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 77.141% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -173.878% |
| SQZ Biotechnologies Company | -64.14 Million USD | 74.684% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 6.517% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 117.267% |
| Mesoblast Limited | -62.38 Million USD | 73.973% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -957.128% |
| Genus plc | 73.7 Million USD | 122.033% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -145.602% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -357.796% |
| Marizyme, Inc. | -34.28 Million USD | 52.633% |
| ContraFect Corporation | -64.99 Million USD | 75.018% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -85.112% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -258.756% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1058.361% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -514.041% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -598.763% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -3034.471% |
| Accustem Sciences Inc. | -3.74 Million USD | -333.427% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 66.33% |
| EV Biologics, Inc. | -1.26 Million USD | -1181.477% |
| Q BioMed Inc. | -617.62 Thousand USD | -2529.091% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 554.591% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -2467.654% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -610.794% |
| Biomind Labs Inc. | -1.03 Million USD | -1469.573% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 264.402% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -126.747% |
| Skye Bioscience, Inc. | -13.54 Million USD | -19.859% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -991.695% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -64852.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -318.04% |
| IMV Inc. | -35.52 Million USD | 54.289% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -2.321% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -549.011% |
| GB Sciences, Inc. | -1.41 Million USD | -1043.614% |
| Alpha Cognition Inc. | -9.7 Million USD | -67.305% |
| HST Global, Inc. | -5303.00 USD | -306104.035% |
| CSL Limited | 4.78 Billion USD | 100.339% |
| Halberd Corporation | -74.27 Thousand USD | -21760.822% |
| Enzolytics Inc. | -2.12 Million USD | -665.211% |
| Resverlogix Corp. | -11.74 Million USD | -38.29% |
| Affymax, Inc. | -14.29 Million USD | -13.592% |
| SYBLEU INC | -141.57 Thousand USD | -11369.863% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -430.131% |
| argenx SE | -216.02 Million USD | 92.483% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 70.657% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 1434.265% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -983.323% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 4386.197% |
| AVAX Technologies, Inc. | -6.11 Million USD | -165.646% |
| Zenith Capital Corp. | -8.6 Million USD | -88.682% |
| Genscript Biotech Corporation | -248.71 Million USD | 93.471% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -93109.345% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -563.734% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -9124.86% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 59.033% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -461.417% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -1451.927% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 241593.159% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -827.886% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -745.328% |
| BioStem Technologies, Inc. | -7.55 Million USD | -114.969% |
| ONE Bio Corp. | 13.61 Million USD | 219.283% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -8866.911% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -689.402% |
| Agentix Corp. | -1.37 Million USD | -1083.738% |
| LadRx Corporation | 412.28 Thousand USD | 4038.557% |
| Cell Source, Inc. | -4.27 Million USD | -280.056% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -4321.86% |
| Regen BioPharma, Inc. | 1.46 Million USD | 1207.673% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -1633.072% |
| NovAccess Global Inc. | -1.03 Million USD | -1469.197% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 283.401% |
| Itoco Inc. | -1.86 Million USD | -768.809% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -4177.435% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1355.018% |
| Kadimastem Ltd | -2.62 Million USD | -518.736% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -6689.881% |
| CytoDyn Inc. | -18.02 Million USD | 9.934% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -20446.888% |
| Mobile Lads Corp. | -2.24 Million USD | -624.536% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -132682.73% |
| Qrons Inc. | -40.08 Thousand USD | -40412.961% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -3243.367% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 3178.685% |
| Rebus Holdings, Inc. | -951 Thousand USD | -1607.466% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -1428.987% |
| International Stem Cell Corporation | 202 Thousand USD | 8138.614% |
| Bioxytran, Inc. | -3.82 Million USD | -325.062% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -30747.264% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -559.563% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 54.73% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -35984.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -493.061% |
| Neutra Corp. | -181.24 Thousand USD | -8859.045% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 19.45% |
| PureTech Health plc | -11.62 Million USD | -39.658% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 19.445% |
| IXICO plc | -707 Thousand USD | -2196.747% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -111.295% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 66.413% |
| CSL Limited | 4.73 Billion USD | 100.343% |
| Cellectis S.A. | -92.63 Million USD | 82.471% |